Proteomic biomarkers of endometrial cancer risk in women with polycystic ovary syndrome: A systematic review and biomarker database integration

Gynecological Endocrinology

Volumn 29, Issue 7, 2013, Pages 638-644

  Galazis, Nicolas ^a   Pang, Yik Lam ^a   Galazi, Myria ^b   Haoula, Zeina ^c   Layfield, Robert ^d   Atiomo, William ^c  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b LUTON AND DUNSTABLE HOSPITAL   (United Kingdom)

^c NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Cancer; Endometrial cancer; Ovary; Polycystic; Proteomics

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENT COMPONENT C4; CYCLOPHILIN A; CYTOSOL AMINOPEPTIDASE; GELSOLIN; GLUTATHIONE TRANSFERASE; MANGANESE SUPEROXIDE DISMUTASE; PEPTIDYLPROLYL ISOMERASE; PYRUVATE KINASE; TRANSGELIN;

CANCER PREVENTION; CANCER RISK; CANCER SCREENING; ENDOMETRIUM CANCER; HUMAN; META ANALYSIS; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; SYSTEMATIC REVIEW;

CARCINOMA, ENDOMETRIOID; DATABASES, PROTEIN; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; POLYCYSTIC OVARY SYNDROME; PROTEOME; PROTEOMICS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84879296045     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2013.777416     Document Type: Review

References (45)

1. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reprod 2004;19:41-7
2. Wild RA. Long term health consequences of PCOS. Human Reprod Update 2002;8:231-41
3. Dunaif A, Thomas A. Current concepts in the polycystic ovary syndrome. Ann Rev Med 2001;52:401-19
4. Fearnley EJ, Marquart L Spurdle AB; Australian Ovarian Cancer Study Group and Australian National Endometrial Cancer Study Group, et al. Polycystic ovary syndrome increases the risk of endometrial cancer in women aged less than 50 years: An Australian case-control study. Cancer Causes Control 2010;21:2303-8
5. Chittenden BG, Fullerton G, Maheshwari A, Bhattacharya S. Polycystic ovary syndrome and the risk of gynaecological cancer: A systematic review. Reprod Biomed Online 2009;19:398-405
6. Pillay OC, Te Fong LF, Crow JC, et al. The association between polycystic ovaries and endometrial cancer. Hum Reprod 2006;21: 924-9
7. Hardiman P, Pillay OS, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. Lancet 2003;361:1810-2
8. Anderson NL, Anderson NG. Proteome and proteomics: New technologies, new concepts, and new words. Electrophoresis 1998; 11:1853-61
9. Atiomo WU, Khalid S, Ziauddin A, et al. Framework for a systems approach to proteomic biomarker profiling in polycystic ovary syndrome. Special report. Expert Rev Proteomics 2009;6:469-99
10. Zaino RJ. FIGO staging of endometrial adenocarcinoma: A critical review and proposal. Int J Gynecol Pathol 2009;28:1-9
11. Parker LA, Gómez Saez N, Lumbreras B, et al. Methodological deficits in diagnostic research using '-omics' technologies: Evaluation of the QUADOMICS tool and quality of recently published studies. PLoS One 2010;5:e11419
12. Choi DH, Lee WS, Won M, et al. The apolipoprotein A-I level is downregulated in the granulosa cells of patients with polycystic ovary syndrome and affects steroidogenesis. J Proteome Res 2010;9: 4329-36
13. Insenser M, Martinez-Garcia MA, Montes R, et al. Proteomic analysis of plasma in the polycystic ovary syndrome identifies novel markers involved in iron metabolism, acute-phase response, and inflammation. J Clin Endocrinol Metab 2010;95:3863-70
14. Misiti S, Stigliano A, Borro M, et al. Proteomic profiles in hyperandrogenic syndromes. J Endocrinol Invest 2010;33:156-64
15. Atiomo W, Khalid S, Parameshweran S, et al. Proteomic biomarkers for the diagnosis and risk stratification of polycystic ovary syndrome: A systematic review. BJOG 2009;116:137-43
16. Santillan I, Neubeck S, Markert UR. Comparative proteomic analysis of follicular fluids from patients with different infertility etiologies. Am J Reprod Immunol 2010;63:52-3
17. Webber M, Neubeck S, Hoppe I, Markert UR. Comparative proteomic analysis of follicular fluids from patients with different infertility etiologies. J Reprod Immunol 2010;86:56-7
18. Cox MC, Borro M, Gentile G, et al. Specific effects exerted by B-lymphoproliferative diseases on peripheral T lymphocytes protein expression. Haematologica 2010;95:176-7
19. Baek KH, Kim YS, Gu BH, et al. Apolipoprotein as a novel gene associated with polycystic ovary syndrome. Fertil Steril 2010;94;4: S197-8
20. Ling J, Zhao KK, Cui YG, et al. Heat shock protein 10 regulated apoptosis of mouse ovarian granulosa cells. Gynecol Endocrinol 2011;27:63-71
21. Peral B, Camafeita E, Fernandez-Real JM. Tackling the human adipose tissue proteome to gain insight into obesity and related pathologies. Expert Rev Proteomics 2009;6:353-61
22. Hojlund K, Mogensen M, Sahlin K. Mitochondrial dysfunction in type 2 diabetes and obesity. Endocrinol Metab Clin North Am 2008; 37:713-31
23. DeSouza L, Diehl G, Rodrigues MJ, et al. Search for cancer markers from endometrial tissues using differentially labeled tags iTRAQ and cICAT with multidimensional liquid chromatography and tandem mass spectrometry. J Proteome Res 2005;4:377-86
24. Wahl H, Daudi S, Kshirsagar M, et al. Expression of metabolically targeted biomarkers in endometrial carcinoma. Gynecol Oncol 2010; 116:21-7
25. Monge M, Doll A, Colas E, et al. Subtractive proteomic approach to the endometrial carcinoma invasion front. J Proteome Res 2009;8: 4676-84
26. Negishi A, Ono M, Handa Y, et al. Large-scale quantitative clinical proteomics by label-free liquid chromatography and mass spectrometry. Cancer Sci 2009;100:514-9
27. DeSouza LV, Krakovska O, Darfler MM, et al. mTRAQ-based quantification of potential endometrial carcinoma biomarkers from archived formalin-fixed paraffin-embedded tissues. Proteomics 2010;10:3108-16
28. Guo J, Yang EC, Desouza L, et al. A strategy for high-resolution protein identification in surface-enhanced laser desorption/ionization mass spectrometry: Calgranulin A and chaperonin 10 as protein markers for endometrial carcinoma. Proteomics 2005;5:1953-66
29. Li Z, Huang C, Bai S, et al. Prognostic evaluation of epidermal fatty acid-binding protein and calcyphosine, two proteins implicated in endometrial cancer using a proteomic approach. Int J Cancer 2008; 123:2377-83
30. Li Z, Zhao X, Bai S, et al. Proteomics identification of cyclophilin a as a potential prognostic factor and therapeutic target in endometrial carcinoma. Mol Cell Proteomics 2008;7:1810-23
31. DeSouza LV, Grigull J, Ghanny S, et al. Endometrial carcinoma biomarker discovery and verification using differentially tagged clinical samples with multidimensional liquid chromatography and tandem mass spectrometry. Mol Cell Proteomics 2007;6:1170-82
32. Dubé V, Grigull J, DeSouza LV, et al. Verification of endometrial tissue biomarkers previously discovered using mass spectrometrybased proteomics by means of immunohistochemistry in a tissue microarray format. J Proteome Res 2007;6:2648-55
33. Stefansson IM, Salvesen HB, Akslen LA. Loss of p63 and cytokeratin 5/6 expression is associated with more aggressive tumors in endometrial carcinoma patients. Int J Cancer 2006;118: 1227-33
34. Velasco A, Pallares J, Santacana M, et al. Promoter hypermethylation and expression of sprouty 2 in endometrial carcinoma. Hum Pathol 2011;42:185-93
35. Kinnula K, Linnainmaa K, Raivio KO, Kinnula VL. Endogenous antioxidant enzymes and glutathione S.transferase in protection of mesothelioma cells against hydrogen peroxide and epirubicin toxicity. Br J Cancer 1998;77:1097-102
36. Gasque P. Complement: A unique innate immune sensor for danger signals. Mol Immunol 2004;41:1089-98
37. Jin ZG, Lungu AO, Xie L, et al. Cyclophilin A is a proinflammatory cytokine that activates endothelial cells. Atheroscler Thromb Vasc Biol 2004;24:1186-91
38. Assinder SJ, Stanton JAL, Prasad PD. Transgelin: An actin-binding protein and tumour suppressor. Int J Biochem Cell Biol 2009;4: 482-6
39. Mazurek S, Boschek CB, Hugo F, Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol 2005;15:300-8
40. Nomura H, Uzawa K, Ishigami T, et al. Clinical significance of gelsolin-like actin-capping protein expression in oral carcinogenesis: An immunohistochemical study of premalignant and malignant lesions of the oral cavity. BMC Cancer 2008;8:39
41. Tanaka K, Sakoda K, Akita H. Studies on leucine aminopeptidase isoenzymes from the clinical and biochemical aspects. Jpn J Gastroenterol 1979;76:1677-87
42. Dhindsa G, Bhatia R, Dhindsa M, Bhatia V. Insulin resistance, insulin sensitization and inflammation in polycystic ovarian syndrome. J Postgrad Med 2004;50:140-4
43. Ptolemy P, Rifai N. What is a biomarker? Research investments and lack of clinical integration necessitate a review of biomarker terminology and validation schema. Scand J Clin Lab Invest Suppl 2010;70:6-14
44. Dudley JT, Butte AJ. Identification of discriminating biomarkers for human disease using integrative network biology. Pacific Symp Biocomput 2009;14:27-38
45. Hlatky MA, Greenland P, Arnett DK; on behalf of the American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council, et al. Criteria for evaluation of novel markers of cardiovascular risk: A scientific statement from the American Heart Association. Circulation 2009;119:2408-16